22nd Century Group CEO James A. Mish to Speak at Cowen 2020 Boston Cannabis Conference

Rhea-AI Summary

22nd Century Group will have its CEO, James A. Mish, participate in a panel at the Cowen 2020 Boston Cannabis Conference on December 2, 2020, focusing on innovations in tobacco and cannabis industries. The panel, moderated by Vivien Azer, will discuss the impact of the election, COVID-19, and current industry trends. One-on-one meetings with investors will occur from November 30 to December 2, 2020. The company aims to reduce smoking harm through reduced nicotine content tobacco products and advance hemp/cannabis research.

WILLIAMSVILLE, N.Y., Nov. 18, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that Chief Executive Officer, James A. Mish, will speak on a panel at the Cowen 2020 Boston Cannabis Conference on Wednesday, December 2, 2020 at 11:50 a.m. EST. The virtual conference is a forum for objective first-hand updates on both marketed and emerging products across the spectrum of the cannabis industry focusing on consumer, technology, and healthcare.

The panel, “Tobacco and Cannabis,” moderated by Vivien Azer, managing director and senior research analyst specializing in tobacco, cannabis, and beverages sectors at Cowen, will feature executives of U.S. cannabis and tobacco operators sharing their on-the-ground reactions to the election, COVID-19, and industry trends.

22nd Century’s management team will also participate in one-on-one meetings with investors during the course of the conference from Monday, November 30, 2020 to Wednesday, December 2, 2020. For more information regarding the Cowen 2020 Boston Cannabis Conference, please visit: https://www.cowen.com/conferences-and-events/3rd-annual-boston-cannabis-conference/.

About 22nd Century Group, Inc.
22nd Century Group, Inc. (NYSE American: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding. 22nd Century’s primary mission in tobacco is to reduce the harm caused by smoking through the Company’s proprietary reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes. The Company’s primary mission in hemp/cannabis is to develop and commercialize proprietary hemp/cannabis plants with valuable cannabinoid profiles and desirable agronomic traits.

Learn more at xxiicentury.com, on Twitter @_xxiicentury and on LinkedIn.

Investor Relations & Media Contact:
Mei Kuo
Director, Communications & Investor Relations
22nd Century Group, Inc.
(716) 300-1221
mkuo@xxiicentury.com 

FAQ

What is the date of the Cowen 2020 Boston Cannabis Conference where XXII's CEO will speak?

The Cowen 2020 Boston Cannabis Conference is on December 2, 2020.

Who will moderate the panel featuring XXII's CEO at the conference?

Vivien Azer will moderate the panel.

What topics will be discussed during the panel at the Cowen conference?

The panel will cover industry reactions to the election, COVID-19, and current trends in tobacco and cannabis.

When will XXII hold one-on-one meetings with investors?

One-on-one meetings with investors will take place from November 30 to December 2, 2020.

What is XXII's mission in the tobacco industry?

XXII's mission is to reduce harm caused by smoking through reduced nicotine content tobacco products.